Prometheus Biosciences
3050 Science Park Road
San Diego
CA
92121
United States
Tel: (858) 824-0895
Website: http://www.prometheusbiosciences.com/
Email: info@prometheusbiosciences.com
About Prometheus Biosciences
Prometheus Biosciences is a biotech company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic product candidates. While our initial focus was on IBD, we're now extending beyond gastrointestinal (GI) diseases to target other autoimmune diseases.
Prometheus360TM, our powerful precision medicine platform, combines proprietary technology with the world's most comprehensive collection of IBD patient data, to translate deep, complex data into precision therapeutic and diagnostic product candidates and continually identify new drug targets and unique disease biomarkers. We're headquartered in San Diego, CA.
The Power of Precision
63 articles about Prometheus Biosciences
-
Addex Therapeutics announced it is canceling its Phase IIb/III study evaluating its drug dipraglurant due to patient recruiting, staffing and pandemic-related issues. -
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
6/8/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced an enrollment update on the APOLLO-CD and ARTEMIS-UC trials.
-
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
5/26/2022
Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will present at the Jefferies Healthcare Conference on June 8, 2022 at 10:00 AM ET.
-
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
5/12/2022
Prometheus Biosciences, Inc. reported financial results for the quarter ended March 31, 2022 and highlighted recent corporate progress.
-
It was a particularly busy week for clinical trial announcements. Let's take a look. -
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
3/30/2022
Prometheus Biosciences, Inc today announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase 2 study of PRA023 in SSc-ILD.
-
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
3/9/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported financial results for the quarter and full-year ended December 31, 2021 and highlighted recent corporate progress.
-
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
3/1/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO along with members of management, will conduct a virtual fireside chat at the Cowen 42nd Annual Healthcare Conference.
-
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
2/7/2022
Prometheus Biosciences, Inc. announced that Mark McKenna, Chairman and CEO, will conduct a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
1/12/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that management will discuss the following updates at the 40th Annual J.P. Morgan Healthcare Conference.
-
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2022
Prometheus Biosciences, Inc. today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST.
-
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone PaymentInvestigational New Drug Application for PR600 expected in 3Q 2022
1/3/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced it has received its final preclinical milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
12/7/2021
Prometheus Biosciences, Inc. today reported positive topline results from its Phase 1 trial of PRA023 in healthy volunteers. It also announced that it is broadening its pipeline by adding a third indication for PRA023, Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), with the initiation of a Phase 2 clinical trial anticipated for the first quarter of 2022.
-
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
11/12/2021
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today reported financial results for the quarter ended September 30, 2021.
-
Abveris Announces Multi-Target, Multi-Year Therapeutic Antibody Discovery Collaboration with Prometheus Biosciences
11/11/2021
Abveris today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets.
-
Prometheus Biosciences to Present at Upcoming Investor Conferences
11/2/2021
Prometheus Biosciences, Inc. today announced that management will be conducting presentations and fireside chats at the following investor conferences in November and December.n
-
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
10/12/2021
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021 at 11:30 a.m. ET.
-
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
8/11/2021
Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease, reported financial results for the quarter ended June 30, 2021, and highlighted recent corporate progress.